

Disclaimer

This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. The Group is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country.

2

Agenda

Highlights	Guillaume Daniellot
Business and regional review	Peter Hackel
ecent achievements and strategy in action	Guillaume Daniellot
utlook 2021	Guillaume Daniellot
&A and upcoming events	Guillaume Daniellot Peter Hackel


straumanngroup

3





Nine-month revenue above 50% growth driven by continued strong patient flow NINE-MONTH REVENUE ORGANIC GROWTH1 DIGITAL TRANSFORMATION CHF 1.5bn +51% Connectivity expanded CHF 496m revenue in Q3 +32% in Q3 3ShapeUnite open dental platform, 10 bps currency effect in Q3 Virtuo Vivo intraoral scanner **IMPLANTOLOGY CUSTOMER FOCUS** OUTLOOK² TLX fully launched Winning DSOs Raised Next phase of immediacy strategy in full swing Further expanding global presence Revenue growth in the high-thirties percentage range, profitability at least at the 2019 level **straumann**group 1 Organic growth excluding FX and M&A effects 2 Barring unforeseen events, assuming the pandemic will not negatively impact the patient flow and excluding FX effects

5











Asia Pacific and Latin America continue to grow Revenue change (organic) **Asia Pacific** China, Japan and Australia 62.8% driving growth Strong contributions from BLX 28.5% 21% of Group* 23.4% 24.5% and digital solutions 11.0% 17.9% Biomaterials introduced in China Q2 Q3 Q3 Q4 Q1 Q3 Q4 Q1 Q2 New direct presence in Malaysia 2019 **2020** -11.7% 2021 **Latin America** 163.6% Brazil, Mexico and Chile leading Orthodontics shows strong growth on small basis 62.5% Neodent strongest brand, 7% of Group* 17.3% 13.4% 7.2% 23.8% premium implants and digital 2.9% solutions performing very well Q3 Q4 Q3 Q4 Q1 Q2 Q3 2019 2020 2021 -60.3% straumanngroup * refers to 9M









Leading role in premium implantology underpinned

- ~10 000 online participants at ITI World Symposium
- Straumann sessions took dentists on a comprehensive educational journey
- Straumann TLX fully launched




straumanngroup

15

Partnering with mininavident to further develop a 3D navigation system for dental implantology

- Digitally guided implant surgery
- Further development of technology to provide a best-in-class platform
- 39% stake in Swiss company mininavident acquired



straumanngroup

16

Strengthening our orthodontics value proposition through enhanced services

- Improved internal software for faster treatment planning
- "Ortho Campus" launched in October featuring orthodontic tools and programs, as well as professional online and in-class education for clinicians and their staff





straumanngroup

____ 17



Investing CHF 18 million in Straumann Group Technology and Innovation Center to support growth strategy

- Existing capacity limited
- Unite expert teams from different locations in the region
 - Warehouse Post, Etkon, Lab Muttenz, Waldenburg
- Strengthening technology and innovation, as well as customer centricity
- Facilitate interdisciplinary cooperation between teams
- Strong commitment to the Basel region





straumanngroup

19



2021 Outlook raised

Market environment

- Dental practices operating with healthy patient flows
- Pandemic-related restrictions limiting spending alternatives, leaving some consumers with more disposable income to spend on specialty dental treatments
- Trend can be expected to gradually soften as spending opportunities further open up
- Pandemic remains unpredictable

Our revenue and profitability¹

- Strong first nine months of 2021
- Group aims to achieve organic revenue growth in the highthirties percentage range
- Profitability (core EBIT margin) expected at least at the 2019 level



straumanngroup

¹ Barring unforeseen events, assuming the pandemic will not negatively impact the patient flow and excluding FX effects

21





Calendar of upcoming events

2021	Event	Location
November 4	ZKB Swiss Equity Conference	Zurich
November 8	UBS European Conference	Virtual
November 17	Credit Suisse Equity Forum Switzerland	Zurich
November 22	Exane BNP Paribas MedTech CEO Conference	Virtual
November 23	JP Morgan North America Roadshow	Virtual
December 7	Credit Suisse European Bus Tour	Virtual
December 16	Capital Markets Day	Hybrid
2022		
February 15	Full- year results	Webcast

straumanngroup

24

